Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin: Via a redox-sensitive prodrug approach promotes synergistic tumor suppression

Venkatesh Teja Banala, Sandeep Urandur, Shweta Sharma, Madhu Sharma, Ravi P. Shukla, Disha Marwaha, Shalini Gautam, Monika Dwivedi, Prabhat Ranjan Mishra

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Rapidly growing evidence suggests a strong dependence of a polyol pathway enzyme Aldose Reductase (AR) in cancer progression and invasion. Thus, inhibiting the AR through therapeutic inhibitors has a potential application in cancer treatment. Epalrestat (EPR) is the only marketed AR inhibitor with proven safety and efficacy in the management of complications like diabetic neuropathy. However, its short half-life and highly hydrophobic nature restrict its use as an anticancer agent. In the present study, we first developed a redox-sensitive prodrug of EPR by conjugating Tocopherol Polyethylene Glycol Succinate (TPGS) which can form a self-assembled micellar prodrug (EPR-SS-TPPGS). Subsequently, to achieve synergistic chemotherapeutic efficacy Doxorubicin (Dox) was co-loaded into the EPR-SS-TPGS micelles where the system is disrupted in a tumor redox environment and co-delivers Dox and EPR in a ratiometric manner. We then employed TPGS conjugated vitamin-B6 as a targeting moiety and prepared the mixed micelles to facilitate VTC receptor-mediated uptake. The encapsulation of Dox and EPR with the developed prodrug approach showed significant synergies with increased intracellular accumulation and redox triggered release in MDA-MB-231 and 4T1 cell lines leading to superior cell cycle arrest, mitochondrial membrane potential, and apoptosis. Prolonged circulation half-life and tumor site bioavailability were achieved for both the drugs with the developed approach. Surprisingly, EPR and Dox combination significantly down-regulated the CD44 receptor expression which is the main contributing factor of tumor metastasis. Furthermore, in vivo evaluation demonstrated a significant reduction in Dox-induced cardiotoxicity. In summary, this nanoencapsulation paradigm of AR inhibitors with chemotherapeutic agents lays the foundation of new opportunities in combination chemotherapy.

Original languageEnglish
Pages (from-to)2889-2906
Number of pages18
JournalBiomaterials Science
Volume7
Issue number7
DOIs
StatePublished - Jul 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin: Via a redox-sensitive prodrug approach promotes synergistic tumor suppression'. Together they form a unique fingerprint.

Cite this